cilgavimab

SARS-CoV-2 neutralizing antibody

Also Known As:

AZD 1061; AZD-1061; AZD1061

Networked: 141 relevant articles (23 outcomes, 29 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        cilgavimab: 141
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        cilgavimab: 141
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        cilgavimab: 141

Experts

1.	Arends, Rosalinda H: 2 articles (10/2022 - 01/2022)
2.	Esser, Mark T: 2 articles (10/2022 - 01/2022)
3.	Garbes, Pedro: 2 articles (10/2022 - 01/2022)
4.	Koh, Gavin C K W: 2 articles (10/2022 - 01/2022)
5.	Padilla, Kelly W: 2 articles (10/2022 - 01/2022)
6.	Pangalos, Menelas N: 2 articles (10/2022 - 01/2022)
7.	Seegobin, Seth: 2 articles (10/2022 - 01/2022)
8.	Streicher, Katie: 2 articles (10/2022 - 01/2022)
9.	Templeton, Alison: 2 articles (10/2022 - 01/2022)
10.	Al Jurdi, Ayman: 1 article (12/2022)

Related Diseases

1.	COVID-19 12/01/2023 - "Therefore, it is important to re-evaluate the real-world efficacy of tixagevimab/cilgavimab for the prevention of COVID-19 in the Omicron era. " 10/01/2022 - "A single intramuscular tixagevimab-cilgavimab dose provided statistically and clinically significant protection against progression to severe COVID-19 or death versus placebo in unvaccinated individuals and safety was favourable. " 09/01/2023 - "Managing SARS-CoV-2 infection in frail and immunosuppressed patients still represents an open challenge, but, starting from the phase 3 PROVENT study, prophylaxis with tixagevimab-cilgavimab has improved the approach in this category of patients, guaranteeing a better outcome and inferior mortality. " 10/20/2023 - "Tixagevimab-cilgavimab is effective for the treatment of early COVID-19 in outpatients with risk factors for progression to severe illness, as well as for primary prevention and post-exposure prophylaxis. " 01/01/2023 - "This study proposes that tixagevimab-cilgavimab was effective and safe for preventing COVID-19. "
2.	Infections 12/01/2022 - "Our study reported a low rate of infections and severe illnesses among immunocompromised patients treated with tixagevimab/cilgavimab. " 10/15/2023 - "In patients treated with tixagevimab/cilgavimab, the rate of infection among patients exposed to SARS-CoV-2 was lower, without reaching statistical significance. " 09/01/2023 - "No patient treated with tixagevimab/cilgavimab experienced symptomatic infection with SARS-CoV-2 during the follow-up (mean observation time of follow-up was 112 ± 23 days), while 11 of 28 controls (39.3%) reported a symptomatic infection (P = .0001), requiring hospitalization in 2 cases. " 09/01/2023 - "Patients treated with tixagevimab-cilgavimab had a mild course of the infection and a reduction of the duration compared with preprophylaxis infection (11 vs. 15 days, p < .001). " 08/02/2023 - "No severe or extended infection was observed in the tixagevimab/cilgavimab group. "
3.	Hematologic Neoplasms (Hematological Malignancy) 12/01/2023 - "A total of 240 consecutive patients with hematologic malignancies received tixagevimab/cilgavimab at our institution from October 18, 2022, to January 31, 2023. " 10/01/2023 - "Reduced prophylactic effect of tixagevimab-cilgavimab in patients with hematological malignancies and without antibody response after SARS-COV-2 vaccination." 01/01/2023 - "Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies." 01/01/2023 - "Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. " 11/01/2023 - "In-depth immunogenicity studies of tixagevimab-cilgavimab (T-C) are lacking, including following breakthrough coronavirus disease 2019 (COVID-19) in vaccinated patients with hematologic malignancy (HM) receiving T-C as pre-exposure prophylaxis. "
4.	COVID-19 breakthrough infections 02/03/2023 - "We aimed at determining the real-world efficacy of tixagevimab and cilgavimab (Evusheld™) in immunosuppressed pwNID in preventing breakthrough COVID-19 infections. " 01/01/2023 - "Clinical studies from 1 January 2021 to 1 October 2022, which reported breakthrough COVID-19 infections after tixagevimab/cilgavimab, were included. " 08/18/2023 - "Risk factors for breakthrough COVID-19 infections in solid organ transplant recipients receiving tixagevimab/cilgavimab for pre-exposure prophylaxis." 02/03/2023 - "In pwNID treated with immunosuppressive therapies, tixagevimab and cilgavimab (Evusheld™) significantly reduced the numbers and severity of breakthrough COVID-19 infections during the Omicron (BA.2-BA.5 variants) wave." 02/03/2023 - "Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study."
5.	Neoplasms (Cancer) 12/01/2023 - "Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies." 01/01/2023 - "Impact of Sars-CoV-2 Prophylaxis with Tixagevimab-Cilgavimab in High-Risk Patients with B-Cell Malignancies: A Single-Center Retrospective Study." 01/01/2023 - "This systematic review and meta-analysis provide an up-to-date summary of the real-world effectiveness of tixagevimab/cilgavimab in immunocompromised patients, including patients with haematological malignancies. " 01/01/2023 - "The use of anti-SARS-CoV-2 antibody products like tixagevimab/cilgavimab represents an important strategy to protect immunocompromised patients with haematological malignancies from COVID-19. " 01/01/2023 - "In order to resume cancer treatment and make the patient free from SARS-CoV-2, an in vitro screening of Evusheld monoclonal antibodies (tixagevumab-cilgavimab) against the viral strains isolated from the subject was performed. "

Related Drugs and Biologics

1.	tixagevimab
2.	Monoclonal Antibodies
3.	cilgavimab and tixagevimab drug combination
4.	Vaccines
5.	sotrovimab
6.	regdanvimab
7.	N-(2-cyanoethylene)urea (BA 1)
8.	N-methyl-valyl-amiclenomycin (BA 2)
9.	Antiviral Agents (Antivirals)
10.	Neutralizing Antibodies

Related Therapies and Procedures

1.	Renal Dialysis (Hemodialysis)
2.	Therapeutics
3.	Stem Cell Transplantation
4.	Hematopoietic Stem Cell Transplantation
5.	Liver Transplantation